➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Baxter
Boehringer Ingelheim
Merck
Dow

Last Updated: September 19, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EC-NAPROSYN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Ec-naprosyn

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00153660 ↗ Celecoxib Versus Naproxen for Prevention of Recurrent Ulcer Bleeding in Arthritis Patients Unknown status Chinese University of Hong Kong Phase 3 2005-06-01 The aim of this study is to compare a PPI (esomeprazole) plus a COX-2 inhibitor (celecoxib) with a PPI plus a nonselective NSAID (naproxen) in preventing recurrent ulcer bleeding in arthritis patients with a history of ulcer. The investigators hypothesized that among patients with a history of ulcer bleeding who receive prophylaxis with a PPI, celecoxib would be superior to naproxen for the prevention of recurrent ulcer bleeding irrespective of concomitant use of aspirin.
NCT00383487 ↗ A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer Terminated Novacea Phase 2 2005-03-01 To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.
NCT00383487 ↗ A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer Terminated Stanford University Phase 2 2005-03-01 To determine whether, in this patient population, treatment with calcitriol and Naproxen is more effective in delaying the growth of prostate cancer than treatment with calcitriol alone as seen in historical controls.
NCT00527904 ↗ A 12-month, Phase 3, Open-label, Multi-center Study to Evaluate the Long-term Safety of PN400 (VIMOVO) Completed POZEN Phase 3 2007-03-01 This study uses an open-label design and will be conducted in approximately 60 sites aiming to enroll a total number of 200 subjects to ensure that at least 100 subjects will have 12 months exposure to PN400 (VIMOVO).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ec-naprosyn

Condition Name

Condition Name for Ec-naprosyn
Intervention Trials
Healthy 4
Osteoarthritis 3
Gastric Ulcer 2
Trauma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Ec-naprosyn
Intervention Trials
Osteoarthritis 3
Stomach Ulcer 3
Migraine Disorders 3
Rib Fractures 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Ec-naprosyn

Trials by Country

Trials by Country for Ec-naprosyn
Location Trials
United States 30
Sweden 4
Canada 4
United Kingdom 2
Saudi Arabia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Ec-naprosyn
Location Trials
New York 2
Maryland 2
North Carolina 2
California 2
Texas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Ec-naprosyn

Clinical Trial Phase

Clinical Trial Phase for Ec-naprosyn
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 2/Phase 3 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Ec-naprosyn
Clinical Trial Phase Trials
Completed 11
Recruiting 6
Unknown status 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Ec-naprosyn

Sponsor Name

Sponsor Name for Ec-naprosyn
Sponsor Trials
AstraZeneca 3
Logical Therapeutics 2
Oxford Pharmascience Ltd 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Ec-naprosyn
Sponsor Trials
Other 17
Industry 13
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
Boehringer Ingelheim
McKesson
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.